Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott announces acquisition of CFR Pharmaceuticals


Friday, 16 May 2014 08:11am EDT 

Abbott Laboratories:To acquire Latin American pharmaceutical company CFR Pharmaceuticals.Abbott to acquire the holding company that indirectly owns about 73pct of CFR Pharmaceuticals and will conduct a public cash tender offer for all of the outstanding shares of CFR.Assuming all publicly-held shares are tendered, the total purchase price would be about $2.9 bin, plus the assumption of net debt of about $430 mln.Assuming the transaction closes as anticipated by the end of the third quarter of 2014.Barclays advised Abbott on the transaction; Deutsche Bank Securities Inc. advised CFR. 

Company Quote

43.81
 --
21 Nov 2014